Reported adverse events following COVID-19 vaccination in gynecologic cancer patients in Thailand: A descriptive study
Table 5
Logistic regression of the association between demographics, clinical factors and the occurrence of any grade adverse events after 1st dose of COVID-19 vaccine (92.9% AstraZeneca).